NSE: APLLTD | BSE: 533573

Mid-range Performer

Download real time

960.10 4.35 (0.46%)

26.37% Fall from 52W High

166.6K NSE+BSE Volume

NSE 04 Sep, 2025 3:31 PM (IST)

18,872

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Alembic Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APLLTD, BSE:533573 Alembic Pharmaceuticals Ltd.

Search Inside the pdf :

Alembic Pharmaceuticals Ltd.

12 Aug 2025

960.10

0.46%

Steady Q1FY26 performance with positive FY26E outlook

Accumulate: Alembic Pharmaceuticals Ltd.

Deven Choksey

We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

06 Aug 2025

960.10

0.46%

Turnaround in US growth; tepid traction in India

Hold: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q1FY26 result was in line with our expectations. Revenue growth was mainly driven by US (13% YoY) and ex-US international business (21% YoY). India growth was tepid at 4.7% YoY due to challenges in specialty portfolio (up 1% YoY) and slowdown in acute market.

Alembic Pharmaceutic.. has an average target of 1001.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

05 Aug 2025, 12:00AM

960.10

0.46%

Export strength offsets muted DF/API show

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered a largely in-line performance for 1QFY26. Superior execution in the export market led to YoY growth in revenue/EBITDA/PAT for the quarter.

Alembic Pharmaceuticals Ltd. is trading above its 200 day SMA of 955.2

Alembic Pharmaceuticals Ltd.

07 May 2025

960.10

0.46%

Alembic Pharma (BUY): FY26 to be better than FY25

Buy: Alembic Pharmaceuticals Ltd.

BOB Capital Markets Ltd.

Revenue/EBITDA/ PAT grew 6.7%/8% and 19% above our estimates. EBITDA margin reported 20bps above estimates of 15.4% in 4QFY25

Number of FII/FPI investors decreased from 198 to 192 in Jun 2025 qtr

Alembic Pharmaceuticals Ltd.

06 May 2025

960.10

0.46%

Exports outshine; API witnesses gradual recovery

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered a better-than-expected performance in 4QFY25. A strong performance in export markets was offset partly by a muted show in domestic formulation (DF) segment.

Alembic Pharmaceuticals Ltd. is trading below its 30 day SMA of 967.3

Alembic Pharmaceuticals Ltd.

12 Feb 2025

960.10

0.46%

Alembic Pharma (BUY): Earnings recovery on normalised Azithromycin base

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

US and ROW sales grew above our estimates of 5% and 13% respectively, reporting growth of 10% each

Alembic Pharmaceuticals Ltd. is trading below its 30 day SMA of 967.3

Alembic Pharmaceuticals Ltd.

04 Feb 2025, 12:00AM

960.10

0.46%

In pursuit of a turnaround

Hold: Alembic Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q3FY25 result was dragged by tepid performance in India and API biz. India biz growth has been weaker (5.8% in 9MFY25) for the last couple of quarters due to pressure in acute segment even though animal health biz has been growing <20%.

Alembic Pharmaceuticals Ltd. is trading above its 200 day SMA of 955.2

Alembic Pharmaceuticals Ltd.

03 Feb 2025

960.10

0.46%

Muted India business and lower operating leverage drag earnings

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered operationally in-line 3QFY25 performance. Higher interest outgo and tax led to lower-than-expected earnings for the quarter.